1. Home
  2. CRDL vs CPSS Comparison

CRDL vs CPSS Comparison

Compare CRDL & CPSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.49

Market Cap

154.1M

Sector

Health Care

ML Signal

HOLD

Logo Consumer Portfolio Services Inc.

CPSS

Consumer Portfolio Services Inc.

HOLD

Current Price

$8.55

Market Cap

179.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDL
CPSS
Founded
2017
1991
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
154.1M
179.3M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
CRDL
CPSS
Price
$1.49
$8.55
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
1.0M
13.5K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1.27
EPS
N/A
0.80
Revenue
N/A
$434,470,000.00
Revenue This Year
N/A
$147.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$10.61
Revenue Growth
N/A
10.41
52 Week Low
$0.88
$6.67
52 Week High
$1.59
$10.22

Technical Indicators

Market Signals
Indicator
CRDL
CPSS
Relative Strength Index (RSI) 69.76 65.18
Support Level $0.95 $7.91
Resistance Level $1.59 $8.82
Average True Range (ATR) 0.10 0.23
MACD 0.01 0.11
Stochastic Oscillator 95.74 97.29

Price Performance

Historical Comparison
CRDL
CPSS

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

Share on Social Networks: